Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.

Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.
复制标题

发现一种靶向SET-PP2A相互作用的小分子以克服慢性粒细胞白血病的BCR-ABLT315I突变

DOI:
10.18632/oncotarget.3665
复制
发表时间:
2015-05-20
期刊:
影响因子:
--
通讯作者:
Chen Y
Chen Y
中科院分区:
其他
文献类型:
--
作者:
Wang S;Xie W;Wang D;Peng Z;Zheng Y;Liu N;Dai W;Wang Y;Wang Z;Yang Y;Chen Y

文献摘要

参考文献

被引文献

相似文献

尽管使用酪氨酸激酶抑制剂(TKIs)治疗慢性粒细胞白血病(CML)取得了巨大的成功,但多药耐药的频繁发生,特别是bcr-abl的T315I突变,仍然是一个具有挑战性的问题。通过解离蛋白磷酸酶2A(PP2A)的内源性抑制物组来提高其活性是对抗TKI耐药的有效途径。在这里,我们报告了一种新的2-苯氧基嘧啶化合物TGI1002的鉴定,该化合物能够特异性地干扰SET-PP2A相互作用。通过与SET结合,TGI1002抑制了SET-PP2A的相互作用,增加了PP2A的活性。此外,下调SET的表达降低了肿瘤细胞对TGI1002的敏感性。TGI1002处理也显著增加bcr-abl的去磷酸化。此外,TGI1002还能显著抑制BaF3-p210T315I细胞移植小鼠的肿瘤生长并延长其存活时间。这些发现表明TGI1002是一种新的SET抑制剂,具有治疗耐药CML的重要潜力。
Despite the great success in using tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML), the frequent development of multi-drug resistance, particularly the T315I mutation of BCR-ABL, remains a challenging issue. Enhancement of protein phosphatase 2A (PP2A) activity by dissociating its endogenous inhibitor SET is an effective approach to combat TKI-based resistance. Here, we report the identification of a novel 2-phenyloxypyrimidine compound TGI1002 to specifically disrupt SET-PP2A interaction. By binding to SET, TGI1002 inhibits SET-PP2A interaction and increases PP2A activity. In addition, knocking-down SET expression decreases tumor cell sensitivity to TGI1002. TGI1002 treatments also markedly increase dephosphorylation of BCR-ABL. Moreover, TGI1002 significantly inhibits tumor growth and prolongs survival of xenografted mice implanted with BaF3-p210T315I cells. These findings demonstrate that TGI1002 is a novel SET inhibitor with important therapeutic potential for the treatment of drug-resistant CML.
DOI: 10.1038/sj.leu.2402257
发表时间: 2001-10-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Blagosklonny, MV;Fojo, T;Neckers, LM
通讯作者: Neckers, LM
DOI: 10.1158/1078-0432.ccr-13-2575
发表时间: 2014-04-15
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
Agarwal A;MacKenzie RJ;Pippa R;Eide CA;Oddo J;Tyner JW;Sears R;Vitek MP;Odero MD;Christensen DJ;Druker BJ
通讯作者: Druker BJ
DOI: 10.1016/j.ccr.2005.10.015
发表时间: 2005-11-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Neviani, P;Santhanam, R;Perrotti, D
通讯作者: Perrotti, D
DOI: 10.1172/jci68951
发表时间: 2013-10-01
影响因子: 15.9
作者:
Neviani, Paolo;Harb, Jason G.;Perrotti, Danilo
通讯作者: Perrotti, Danilo
在爆炸危机和抗伊马替尼的慢性骨髓性白血病中重置PP2A肿瘤抑制活性。
DOI: 10.1038/sj.bjc.6603317
发表时间: 2006-10-09
影响因子: 8.8
作者:
Perrotti, D;Neviani, P
通讯作者: Neviani, P